Self-developed NKT autologous natural killer immune cell preparations PB101 has legally passed phase I clinical trial, and has now entered phase II clinical trial (for EGFR non-small cell lung cancer patients); safety and tolerability of all patients participating in the treatment are 100% safe and 100% effective. Cells amplified from 1X106 to 8X109 Effective amplification by 8000 times. Among them, 66.7% of the tumors in the cancer site were significantly reduced, and the condition was stable and did not deteriorate. Patients with advanced non-small cell lung cancer have been treated since 2018 and are still alive.
Successfully independently developed NK allogeneic natural killer immune cell preparation PB103/In vitro expansion up to 10,000 times; Cell high purity 99%,Cell survival rate 95%; No serum culture medium; Self developed cryopreservation tech and other cutting-edge technology. Allogeneic NK immune cell preparations PB103 passed TFDA approved phase I/II clinical trial on August 26, 2020, and entered phase I/IIa clinical trial at the same time. The special control law of Taiwan government allows patients to use our PB101-103 series products for fee-based treatment.
Are used in clinical trial cases of PB103 allogeneic NK phase I/IIa and of PB101 autologous NK/NKT in Taiwan. The targeting indications are safety and tolerance evaluation of advanced non-small cell lung cancer.
Are used in clinical trial cases of PB103 allogeneic NK phase I/IIa and of PB101 autologous NK/NKT in Taiwan. The targeting indications are safety and tolerance evaluation of advanced non-small cell lung cancer.
Used in preclinical trials for cancer vaccines and antibodies by cooperating with well-known pharmaceutical factories in Taiwan, which currently include ex vivo trials and ongoing in vivo trials targeting triple-negative breast cancer.
Used in technology cooperation with Japan Jingao Enterprise, namely DC cell transfer technology for the development of a variety of solid cancer therapies
Clinical Trials